Clearpoint Neuro Inc

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ClearPoint Neuro reports revenue growth, faces margin pressures in 2022

ClearPoint Neuro's financial performance in 2022 showed revenue growth but faced margin pressures and increased operating expenses.
The company's strengths lie in revenue growth projections, successful product launches, and cost-saving initiatives.
Challenges include post-COVID operational disruptions, supply chain concerns, and achieving cash breakeven targets.
Opportunities exist in R&D investments, international expansion, and maintaining an optimistic outlook for future growth.

ClearPoint Neuro reports Q1 growth, targets $50M revenue by 2025

ClearPoint Neuro Inc's Q1 performance reflects steady revenue growth and strategic investments to drive future expansion and innovation.
While facing challenges in certain revenue segments and margin decline, the company's strong growth strategy and focus on key areas present opportunities for sustained success.
With a clear roadmap to achieve revenue targets, expand partnerships, and launch new products, ClearPoint is poised for continued growth and market leadership in the neurosurgery sector.

ClearPoint Neuro reports record revenue and growth strategy focus

ClearPoint Neuro Inc's Q2 2023 earnings call highlighted record revenue, growth pillars, and operational efficiency improvements. Challenges include installation barriers and regulatory expansions, while opportunities lie in neuro-oncology expansion and pharma partnerships. The company aims for cash flow breakeven by 2025 and emphasizes long-term pharma relationships.

ClearPoint Neuro reports improved Q3 performance amidst strategic growth plans

ClearPoint Neuro's Q3 2023 performance showed improvements in operational cash burn and revenue growth in key segments, despite challenges in gross margin and operating expenses.
The company's strategic focus on innovation, patient outcomes, and market expansion presents opportunities for sustained growth and competitiveness in the healthcare sector.
While facing challenges in cost management and market access, ClearPoint Neuro is well-positioned to leverage opportunities in new revenue streams, product launches, and operational enhancements.
Overall, ClearPoint Neuro's commitment to improving patient outcomes, expanding market reach, and driving innovation underscores its potential for future success and growth.

ClearPoint Neuro reports robust Q4 earnings, eyes growth opportunities

ClearPoint Neuro's strong Q4 performance and revenue growth in 2023 position the company well for 2024. Despite challenges with EU MDR certification, ClearPoint is investing in partnerships to overcome regulatory hurdles. Opportunities for growth include new product releases and expanding market presence.

ClearPoint Neuro reports 41% revenue growth in Q1 2024

ClearPoint Neuro's Q1 2024 earnings call showcased robust revenue growth, controlled expenses, and a strategic focus on key growth areas. The company's optimistic outlook for 2024 is supported by strong demand from pharmaceutical partners and expansion initiatives.

ClearPoint Neuro reports record revenue growth and raises full-year guidance

ClearPoint Neuro's Q2 2024 performance reflects robust revenue growth and a solid financial position.
The company's focus on key growth pillars and increased revenue guidance for the year signal a positive outlook for future expansion.
While challenges in cost management and market competition exist, ClearPoint Neuro's strengths and opportunities position it well for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease

SOLANA BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 12:00 p.m. Eastern Time.

ClearPoint Neuro to Present at the UBS Global Healthcare Virtual Conference

SOLANA BEACH, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing navigation and delivery to the brain, today announced the first human cases of the SmartFrame Array Neuro Navigation System and Software. The ‘Array' system is designed to streamline workflows and reduce procedure time in both the MRI Suite and in the Operating Room. The Company believes the added flexibility of a potential Operating Room placement will allow more hospital sites and surgeons to access ClearPoint's technology and clinical support.

ClearPoint Neuro, Inc. Announces First-in-Human Cases of the SmartFrame Array™ Neuro Navigation System and Software

Clearpoint Neuro's (CLPT) CEO Joe Burnett on Q1 2021 Results - Earnings Call Transcript

SOLANA BEACH, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2021.

ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array'

SOLANA BEACH, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a partnership with San Diego-based D&K Engineering for the continued development of a robotic system for use in both the MRI Suite and the Operating Room.

ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating Room

ClearPoint Neuro, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ClearPoint Neuro, Inc. (CLPT) Q1 Earnings Expected to Decline

SOLANA BEACH, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 first quarter, which ended March 31, 2021, on Tuesday, May 11, 2021, after the market close.

ClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021

SOLANA BEACH, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates Voyager Therapeutics on receiving FDA clearance of the IND application for their gene therapy candidate VY-HTT01 for the treatment of Huntington's disease.

ClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington's Disease

SOLANA BEACH, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that on September 14, 2020, the Company's Board of Directors approved the grant to Mr. Danilo D'Alessandro of (i) 30,000 shares of restricted common stock and (ii) a non-qualified stock option awards to purchase 75,000 shares of common stock with an exercise price of $5.80, the closing price on his start date, September 29, 2020. The stock option and restricted share awards will vest in three equal annual installments beginning on September 29, 2021. These awards were granted as an inducement equity award outside of the Company's 2013 Incentive Compensation Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by Mr. D'Alessandro. The options and restricted shares are further subject to the terms and conditions of the award agreements that are exhibits to Mr. D'Alessandro's employment agreement, which was filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on September 14, 2020, and were previously reflected on Mr. D'Alessandro's Form 4 filed with the SEC on September 30, 2020.

ClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOLANA BEACH, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the upcoming retirement of John N. Spencer, Jr. from its Board of Directors. Mr. Spencer, who has as served as a director since March 2010, is retiring when his current term of office expires effective at ClearPoint's Annual Meeting of Stockholders to be held on June 3, 2021.

ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.

IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates uniQure N.V. on the early completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 being conducted in the United States for the treatment of early-stage Huntington's disease.

ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

Potential for 100 gene therapy trials to be using ClearPoint. Expect significant growth in 2H 2021 as elective surgeries rebound and clinical trials restart.

ClearPoint Neuro: A Biotech Portfolio Play

IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team.

ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel

ClearPoint Neuro, Inc. (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ClearPoint Neuro, Inc. (CLPT) Surges 12.8%: Is This an Indication of Further Gains?

Clearpoint Neuro, Inc. (CLPT) CEO Joseph Burnett on Q4 2020 Results - Earnings Call Transcript

Shares of ClearPoint Neuro (NASDAQ:CLPT) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 18.18% over the past year to ($0.09), which beat the estimate of ($0.13).

Recap: ClearPoint Neuro Q4 Earnings

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the closing of its previously disclosed public offering of common stock. The total number of shares of common stock sold was 2,127,660, composed of 1,850,140 shares of common stock initially offered at a public offering price of $23.50 per share and an additional 277,520 shares of common stock sold pursuant to the exercise of the underwriters' option to purchase additional shares at the price of $22.09 per share. The net proceeds to the Company from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $46.8 million. The Company will use the net proceeds from the offering to fund product development and research and development activities and the remainder for working capital and general corporate purposes.

ClearPoint Neuro Announces Closing of Public Offering of 2,127,660 Shares of Common Stock

IRVINE, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2020 fourth quarter and full year, which ended December 31, 2020, on Thursday, March 4, 2021, after the market close.

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2020 Results on March 4, 2021

ClearPoint Neuro Inc (NASDAQ: CLPT) has priced its underwritten public offering of 1.85 million shares at $23.50 per share, representing a 9% discount on the last close price of $25.80 on Thursday. Gross proceeds to the company are approximately $43.4 million.

ClearPoint Neuro Secures $43M Via Equity At 9% Discount

IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the pricing of its underwritten public offering of 1,850,140 shares of its common stock at a price to the public of $23.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 277,520 shares of its common stock at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on February 23, 2021, subject to customary closing conditions.

ClearPoint Neuro Announces Pricing of Public Offering of 1,850,140 Shares of Common Stock

IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the commencement of a proposed underwritten public offering of its shares of common stock. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™' Brain Model by 2022

ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips

Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets

News for Clearpoint Neuro Inc Stock (CLPT)